JPRN-jRCT2080220603未知2 期
A Phase 2/3 Study of SYR-322 as an Add-on to a Sulfonylurea
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Key Criteria for inclusion:
- •The subject has been taking a sulfonylurea for at least 4 weeks prior to the initiation of the observation period.
- •The subject has been taking sulfonylurea at a stable dose regimen for at least 12 weeks prior to the initiation of the treatment period(Week 0).
- •The subject has an HbA1C of 7.0% or more and below 10.0% at 8 weeks after the initiation of the observation period(Week -4).
排除标准
- •Key Criteria for exclusion:
- •The subject has taken other diabetic medications than sulfonylurea within 12 weeks before the initiation of the treatment period (Week 0).
研究者
相似试验
已完成
不适用
A Phase 2/3 Study of SYR-322 as an Add-on to a SulfonylureaType 2 diabetes mellitusJPRN-UMIN000001393Takeda Pharmaceutical Company Limited240
已完成
不适用
A Phase 2/3 Study of SYR-322 as an Add-on to an Alpha-Glucosidase InhibitorType 2 diabetes mellitusJPRN-UMIN000001381Takeda Pharmaceutical Company Limited210
已完成
不适用
A Phase 2/3 Study of SYR-322 as an Add-on to a MetformiType 2 diabetes mellitusJPRN-UMIN000001394Takeda Pharmaceutical Company Limited240
未知
2 期
A Phase 2/3 Study of SYR-322 as an Add-on to a MetformiType 2 diabetes mellitusJPRN-jRCT2080220606Takeda Pharmaceutical Company Limited240
未知
2 期
A Phase 2/3 Study of SYR-322 as an Add-on to a ThiazolidineJPRN-jRCT2080220568Takeda Pharmaceutical Company Limited240